MedTrace Logo

Elimination of Odor and Treatment of Malodorous Recalcitrant Wounds by Using Supraz and PRP-FG Versus Standard of Care

NCT05983302 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2026-05-06

No results posted yet for this study

Summary

The aim of this study is to eliminate the malodorous of chronic wound and increase the chance of the healing of recalcitrant wounds by using the repairing gel (supraz gel) which has the approved components in wound healing and platelet-rich plasma-fibrin glue.

Conditions

  • Wounds and Injuries

Interventions

DRUG

Repairing Gel

The second intervention group includes 10 patients with chronic wounds who, despite common treatment, will be undergone the repairing gel with approved wound healing components in the form of gel for 8 weeks.

DRUG

Repairing Gel and Platelet-Rich Plasma-Fibrin Glue

The third intervention group includes 10 patients with chronic wounds who, despite common treatment, will be undergone the repairing gel with approved wound healing components in the form of gel and PRP-FG for 8 weeks.

OTHER

Classical wound irrigation (control)

For 10 patients with chronic wounds, only the classical wound irrigation by normal saline will be continued for 8 weeks.

DRUG

Platelet-Rich Plasma-Fibrin Glue

The first intervention group includes 10 patients with chronic wounds who, despite common treatment, will be undergone PRP-FG intervention for 8 weeks.

Sponsors & Collaborators

  • Mashhad University of Medical Sciences

    lead OTHER

Principal Investigators

  • Daryoush Hamidi Alamdari, Ph.D · Surgical Oncology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.

  • Daryoush Hamidi Alamdari · Surgical Oncology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
FACTORIAL

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-08-20
Primary Completion
2024-01-20
Completion
2027-03-20

Countries

  • Iran

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05983302 on ClinicalTrials.gov